TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PROMINENT-Eye Ancillary Study (Protocol AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Already randomized at US or Canadian sites in the PROMINENT study~* Ability to cooperate with dilated ophthalmic examination and imaging procedures~* At least one eye meets the following study eye inclusion criteria:~  1. Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity level between 20 and 53 (minimal to severe non-proliferative diabetic retinopathy (NPDR)), inclusive, on color fundus photographs confirmed by central Reading Center grading.~Exclusion Criteria:~* Study eye exclusion criteria are:~  a. Neovascularization present. b. Current central-involved diabetic macular edema (DME based on optical coherence tomography (OCT) central subfield thickness (CST) i. Zeiss Cirrus: CST ≥ 290µm in women or ≥ 305µm in men ii. Heidelberg Spectralis: CST ≥ 305µm in women or ≥ 320µm in men c. Known major non-diabetic intraocular pathology that in the opinion of the investigator would substantially and adversely affect visual acuity or lead to ocular neovascularization during the course of the study d. Anticipated need for intravitreous anti-vascular endothelial growth factor (VEGF), intravitreous corticosteroid, or pan-retinal photocoagulation (PRP) in the next 6 months following randomization e. History of intravitreous anti-VEGF or corticosteroid treatment within the prior year for any indication.~  f. History of intraocular surgery within prior 4 months or anticipated within the next 6 months following randomization g. Any history of PRP or vitrectomy h. History of yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to screening i. Aphakia j. Known substantial media opacities that would preclude successful imaging

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemafibrate (Type: EXPERIMENTAL): .2 mg pemafibrate orally BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pill orally BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 to 75 years of age.~* ECOG performance status of 0, 1 or 2.~* Patients who have a history of another malignant disorder are eligible, provided that they have not received active therapy for 5 years. Patients with basal cell and squamous cell skin cancers are eligible.~* Patients who are pregnant are ineligible.~* Patients must furnish written informed consent and HIPAA authorization for release of personal health information.~* Patients must be able to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments.~* Patients must be HIV and HTLV-I,-II antibody sero-negative.~* Patients must have adequate visceral organ function~Exclusion Criteria:~* Patients are ineligible if they have received cumulative chemotherapy doses in excess of: carmustine (BCNU) 400 mg/m2, or a cumulative anthracycline exposure in excess of 550 mg/m2 Adriamycin (doxorubicin) unless the gated-pool radionuclide cardiac scan shows greater than/equal to 45% ejection fraction.~* Patients are ineligible if they are receiving any other investigational agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Maintenance Lenalidomide After Melphalan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Binet Stage A Chronic Lymphocytic Leukemia (CLL)~* WHO performance status of 2 or less.~* A life expectancy of at least one year.~* Greater than 18 years of age.~* Availability of CLL cells which can be used for DNA extraction and processing.~* A platelet count greater than 100 x 109/l.~* Ability to provide full informed consent.~Exclusion Criteria:~* Previous chemotherapy or radiotherapy.~* Presence of a monoclonal band on serum electrophoresis.~* Presence of clinically significant levels of anti-DNA antibodies, anti-muscle antibodies or rheumatoid factors or who have active autoimmune disease.~* Presence of antibodies to human immunodeficiency virus (HIV) and known carriers of hepatitis B or hepatitis C virus.~* Presence of other serious medical condition e.g. congestive heart failure.~* Presence of other malignancies.~* Pregnancy, lactation, or not using contraceptive measures.~* Concurrent use of other anti-cancer therapy.~* Patients allergic to tetanus vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Granulocytapheresis in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe plaque psoriasis with a PASI \>/=10~* Age \>/= 18 years~* Negative pregnancy test in woman of childbearing age acceptable method of contraception for both men and women~* Written informed consent that can be withdrawn at any time or for any reason~* Discontinuation of any systemic psoriasis treatment. Washout period of at least two weeks for prior systemic medications~* Only emollients for topical treatment~* No vaccinations for at least 14 days prior to first treatment~Exclusion Criteria:~* Other forms of psoriasis (e.g., guttate, pustular, erythrodermic, palmoplantar etc.)~* History of ongoing uncontrolled bacterial, fungal or viral infection (including opportunistic infections); HIV positivity~* Pregnancy~* Clinically relevant thrombocytopenia or bleeding disorders~* WBC \<4.000 or \>12.000/µl~* Malignancy within the last five years (exception: successfully treated basal cell carcinoma or squamous cell carcinoma of the skin)~* Severe cardiac disorders, stroke, pulmonary disease within the last year~* Any medical condition that, in the judgment of the investigators, would jeopardize the patient's safety during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Granulocytapheresis treatment
- B (Type: PLACEBO_COMPARATOR): Sham device treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Intrauterine Device (IUD) Self Removal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* English or Spanish speaking~* Present to Boston Medical Center Yawkey for removal of IUD and have been consented for removal~* Are eligible for removal of IUD in the office setting~Exclusion Criteria:~* Current incarceration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Participants consented for IUD removal (Type: EXPERIMENTAL): Participants will be shown an educational video about IUD self-removal and simulation models. After the video, participants will be given the choice to either attempt IUD self-removal or to have their provider perform standard removal. If a participant elects to attempt self-removal and fails, their provider will offer standard removal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of a New Ambulatory Multi-vital Signs Monitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Inclusion Criteria~  * Age\>18 years~ * Scheduled for surgery from an outpatient setting and scheduled for a pre-admission PAC appointment~ * Risk stratification placing them in the top 25th percentile using our internally-validated PAC Risk Score.~* Exclusion Criteria~  * Surgery on the day of admission (same-day surgery)~ * Any upper extremity surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Caretaker Device (Type: EXPERIMENTAL): participants will undergo active CareTaker monitoring for 24-48 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with open angle glaucoma patients at the Rocky Mountain Lions Eye Institute Glaucoma Clinic.~* Able to provide written informed consent to participate.~* Must be the age of 18 years of age or older.~* Patients in which further intraocular pressure lowering by selective laser trabeculoplasty is necessary in the opinion of the treating physician.~Exclusion Criteria:~* Patients with eye surgery in the prior six months.~* Patients with prior or current use of topical or systemic corticosteroids or NSAIDs.~* Patients with pre-existing anterior chamber inflammation.~* Patients with known sensitivity to any of the study medications.~* Due to the age range and the disease entity, special patient populations such as children or pregnant women will not be enrolled in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acular LS (Type: ACTIVE_COMPARATOR): Acular LS - 1 drop in treated eye, 4 times a day, for 4 days
- Pred Forte (Type: ACTIVE_COMPARATOR): Pred Forte - 1 drop in treated eye, 4 times a day, for 4 days
- Refresh Tears (Type: PLACEBO_COMPARATOR): Refresh Tears - 1 drop in treated eye, 4 times a day, for 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AVJ Ablation Followed by Resynchronization Therapy in Patients With CHF and AF

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic permanent AF~* Class I or II indication for ICD~* LVEF ≤ 35% within 6 months~* NYHA class II or III with a history of CHF~* Maximal tolerated drug therapy for CHF and rate control with a stable regimen for ≥ 30 days~* Ability to independently comprehend and complete a QoL questionnaire~* Ability to give informed consent for study participation and willingness and ability to comply with prescribed follow-up tests and scheduled evaluations~Exclusion Criteria:~* Paroxysmal or persistent AF~* Class I indication for pacing (including AVJ ablation for poor rate control)~* Ability to walk ≥ 450 meters in 6 minutes~* Musculoskeletal disorders that prohibit the completion of a 450 meters walk~* NYHA class I or IV at the time of enrollment~* A contraindication to taking Coumadin therapy~* History of myocardial infarction, percutanous coronary intervention, or CABG in the past 30 days~* History of mitral valve surgery~* Prior attempts for cardiac resynchronization therapy~* The presence of an existing coronary sinus lead or epicardial lead~* Life expectancy \< 1year~* Age \< 18 yrs~* Current participation in other clinical studies except registry trials~* Use of calcium channel blockers~* Pregnancy~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT-D + AVJ Ablation (Type: None): None
- Single-Chamber ICD + Pharmacological Therapy (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib for Thyroid Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Recent diagnosis of thyroid eye disease (within the past 3 months)~* Have ocular symptoms or signs of TED with a clinical activity score (CAS) of at least 3~Exclusion Criteria:~* Pregnancy~* Previous treatment with corticosteroid for TED for \>2wks~* Previous treatment with orbital radiation for TED~* Impaired renal function~* Impaired hepatic function~* Treatment with antihypertensive medications except beta-blockers~* History of congestive heart failure, cardiac valvular disease, or coronary artery disease~* Allergy to NSAID or previous adverse reaction (ie. GI bleeding)~* Vision loss due to compressive optic neuropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: EXPERIMENTAL): Patients who are randomized to treatment with celecoxib 100mg pills by mouth twice a day for 3 months, in addition to standard of care treatment as described under the Control arm
- Control (Type: ACTIVE_COMPARATOR): Patients who are randomized to standard treatment (requiring no prescription medication, but standard recommendations such as artificial tears, avoiding cigarette smoke)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PCI Imaging System in Pediatric Ophthalmology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
* Exclusion Criteria:~  * Any patient who has a cloudy cornea.~ * Any patient whose RetCam imaging exam easily produces blanching of the optic nerve in the normal course of imaging.~ * Any patient who has consented to the procedure, but whose course of examination has filled the time allotted, leaving no time to evaluate the COSMOS.~* Inclusion Criteria:~  * Current patients undergoing clinically indicated EUA and RetCam imaging for surveillance and treatment of ophthalmic conditions at The Hospital for Sick Children.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCI imaging system (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Screening for Familial Gastric Cancer in First Degree Relatives

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult (≥ 18 yrs), female and male relatives~* fully legal competent (to simplify the common consent agreement for blood withdrawal, DNA analysis and serial endoscopies.)~* individuals that signed the common consent agreement~* first degree relative of an individual with diffuse gastric cancer from a FDGC-family, without proven mutation,~  * OR: 2 or more individuals with gastric carcinoma, at least one \< 50 yrs~ * OR: 3 or more individuals with (diffuse/intestinal/other type) gastric carcinoma, any age~ * OR 1 individual with any type gastric carcinoma \< 40 yrs~Exclusion Criteria:~* immature individuals~* actual gastric ulcer or gastric bleeding~* previous diagnosis of gastric cancer~* hypersensitivity to Indigocarmine~* individuals with co-morbidity which might increase the sedation and/or endoscopy risk: COPD Gold III/IV Cardiac failure Increased bleeding tendency or use of medication which increases bleeding tendency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Endoscopy without staining of the mucosa (Type: NO_INTERVENTION): None
- Endoscopy with staining of the mucosa. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients scheduled for major spine surgery at LLUMC University Hospital will be eligible for participation in this study~Exclusion Criteria:~* age under 18yr,~* coagulopathy, significant renal or hepatic dysfunction (creatinine or liver enzymes \> 50% above normal values),~* congestive heart failure,~* cardiac arrhythmias producing irregular rhythms, and patient refusal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard fluid management (Type: NO_INTERVENTION): Standard intraoperative fluid management as determined by usual monitoring and decision making applied by anesthesiology team
- Vigileo model number MHM1 (Type: OTHER): Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV\>12%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: RCT of the Double Wire Technique for Sphincterotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. All patients presenting to Mayo Clinic Arizona for an ERCP who have a native papilla~2. Failure to deeply cannulate the CBD in over 5 minutes and with more than 5 attempts~3. Stable wire placement into the Pancreatic duct (PD) exclusion criteria~1. Any contraindication to undergoing an ERCP. 2. Contraindications to sphincterotomy. 3. Pancreas divisum.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Transpacnreatic sphincterotomy (Type: EXPERIMENTAL): In patients randomized to TPS, a transpancreatic sphincterotomy will be performed with the sphincterotome superficially in the pancreatic duct over a wire.
- Double wire without sphincterotomy (Type: NO_INTERVENTION): In patients randomized to the DWT group, the PD wire will be left in place, the catheter removed and then reinserted next to the PD wire with a second wire to attempt CBD cannluation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mortality Reduction in Septic Shock by Plasma Adsorption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all patients admitted to the ICU in septic shock~* all patients that develop septic shock while in the ICU~Exclusion Criteria:~* Age less than 18 years~* Pregnancy~* Estimated life expectancy (due to comorbidities) less than 90 days~* Presence of relative or absolute contraindications to CPFA~* Absence of informed consen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High doses CPFA (Type: EXPERIMENTAL): High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): \>0.20 L/kg/day of plasma treated in the first 3 days after randomization
- Control Group (Type: NO_INTERVENTION): Standard practice

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Materialise X-ray Knee Guides for Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Physically and mentally able and willing to comply with the protocol~* Be treated for a primary total knee arthroplasty~* Are fluent in Dutch or French~* Sign the Informed Consent Form~* Comply with the indications listed in the Instructions for Use~* Be able to undergo a CT scan~Exclusion Criteria:~* Fulfilling one of the contraindications mentioned in the Instructions for Use~* Pregnant~* A prisoner~* Reported to have mental illness or belonged to a vulnerable population

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- X-Ray Knee Guide group (Type: EXPERIMENTAL): Total knee arthroplasy using Materialise X-Ray Knee Guides

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility